Ketamine Compounding Regulations in 2026: What Has Changed

The Regulatory Landscape in 2026

The regulatory environment surrounding compounded ketamine has undergone significant changes heading into 2026. As the use of ketamine for psychiatric and pain conditions has expanded — particularly through telehealth prescribing and at-home administration models — federal and state regulators have moved to establish clearer rules governing how compounded ketamine is produced, prescribed, and distributed.

These developments have direct implications for patients, prescribers, compounding pharmacies, and the rapidly growing telehealth ketamine industry. Understanding the current regulatory framework is essential for anyone involved in ketamine therapy.

Federal Developments

FDA Enforcement Priorities

The FDA has continued to draw a distinction between two categories of compounding:

• 503A compounding: Traditional compounding by a licensed pharmacy in response to an individual patient prescription. These pharmacies operate under state pharmacy board oversight with limited federal regulation.
• 503B outsourcing facilities: Larger-scale compounding operations that register with the FDA and are subject to Current Good Manufacturing Practice (cGMP) requirements and FDA inspection.

In 2025 and early 2026, the FDA has intensified scrutiny of 503B outsourcing facilities producing ketamine, particularly those supplying large volumes to telehealth companies. Several warning letters and enforcement actions have focused on:

• Quality control failures: Inadequate potency testing, contamination risks, and inconsistent dosing in compounded ketamine products
• Improper distribution practices: 503B facilities shipping compounded ketamine without valid patient-specific prescriptions, effectively functioning as drug manufacturers without New Drug Application (NDA) approval
• Marketing violations: Companies making unapproved therapeutic claims about compounded ketamine, particularly for indications not established by rigorous clinical evidence

DEA Telehealth Prescribing Rules

The Drug Enforcement Administration's evolving telehealth prescribing framework continues to shape compounded ketamine access. Following the expiration of COVID-era telehealth flexibilities, the DEA has implemented new rules for prescribing Schedule III controlled substances via telehealth. Key provisions include:

• Initial in-person evaluation requirements for some patient categories, though exceptions exist for established patient-provider relationships
• State-specific registration requirements for prescribers conducting telehealth across state lines
• Enhanced documentation standards for telehealth encounters involving controlled substance prescriptions
• Prescription monitoring program (PMP) checking mandates before prescribing ketamine via telehealth

For detailed background on the DEA's telehealth framework, see our coverage of DEA telehealth prescribing developments.

Compounding Quality Standards

The FDA has proposed updated draft guidance on compounding quality standards that would affect ketamine preparations. Proposed changes include:

• Stability testing requirements: Compounding pharmacies may be required to conduct beyond-use date testing for ketamine formulations, particularly oral and sublingual preparations
• Potency verification: Enhanced requirements for analytical testing to verify that each compounded dose contains the labeled amount of ketamine within specified tolerances
• Ingredient sourcing: Stricter rules on the sourcing of bulk ketamine powder used in compounding, with emphasis on verifying that active pharmaceutical ingredient (API) suppliers meet quality standards

State-Level Regulatory Changes

Varied Approaches Across States

State pharmacy boards and medical boards continue to implement their own regulations on ketamine compounding and prescribing, creating a patchwork of rules that varies significantly by jurisdiction. Several trends have emerged in 2025 and 2026:

States Tightening Restrictions

Some states have moved to restrict at-home ketamine use or increase oversight of compounding practices:

• Enhanced requirements for in-person evaluations before prescribing compounded ketamine for at-home use
• Mandated follow-up protocols, including required check-in visits within specified timeframes after initiating treatment
• Limitations on the quantity of compounded ketamine that can be dispensed at one time (for example, restricting prescriptions to a 30-day supply)
• Requirements for compounding pharmacies to report ketamine dispensing data to state prescription drug monitoring programs

States Expanding Access

Other states have taken steps to facilitate access to compounded ketamine therapy:

• Explicit authorization of telehealth prescribing for ketamine under defined conditions
• Streamlined licensing pathways for out-of-state compounding pharmacies serving patients within the state
• Clarification that compounded ketamine for psychiatric use is within the scope of practice for psychiatrists, psychiatric nurse practitioners, and other qualified prescribers

For a broader overview of state-by-state regulation, see our state ketamine regulations article.

Pharmacy Board Actions

Several state pharmacy boards have issued guidance or taken enforcement actions related to ketamine compounding in 2026:

• Inspections: Increased inspection frequency of pharmacies compounding ketamine, with particular attention to pharmacies filling high volumes of telehealth prescriptions
• Formulation restrictions: Some boards have limited the types of ketamine formulations that may be compounded (for example, restricting nasal spray compounding to 503B facilities)
• Labeling requirements: New mandates for patient-facing labeling on compounded ketamine products, including warnings about storage, misuse potential, and the need for medical supervision

Impact on Telehealth Ketamine Companies

Business Model Adjustments

The at-home ketamine telehealth industry has been directly affected by regulatory changes. Companies that built their models on rapid telehealth evaluations and mail-order compounded ketamine have been forced to adapt:

• Longer evaluation processes: Many companies have extended their initial psychiatric evaluations from brief video calls to more comprehensive assessments meeting evolving regulatory standards
• In-person components: Some companies have partnered with local clinics or laboratory networks to facilitate required in-person touchpoints
• Pharmacy partnerships: Shifts in which compounding pharmacies companies work with, as some pharmacies have exited the ketamine market due to increased regulatory burden
• Pricing changes: Compliance costs have been passed on to consumers in some cases, affecting the cost of ketamine therapy

Safety Improvements

It is worth noting that many regulatory changes have been motivated by legitimate safety concerns. Reports of adverse events associated with unsupervised at-home ketamine use — including falls, dissociative episodes without adequate monitoring, and rare cases of misuse — have provided the impetus for tighter oversight. For context on at-home safety considerations, see is at-home ketamine safe?.

Impact on Patients

Access and Availability

The net effect of regulatory changes on patient access is mixed:

• Patients in well-regulated states may experience more consistent quality and safety standards, but potentially longer wait times and higher costs
• Patients in restrictive states may face new barriers to accessing at-home ketamine, including requirements for in-person visits that are difficult for patients with mobility limitations or those in rural areas
• Insurance considerations: Compounded ketamine remains largely uncovered by insurance. Regulatory developments have not materially changed the insurance coverage landscape for compounded formulations

What Patients Should Know

Patients currently receiving or considering compounded ketamine therapy should be aware of several practical considerations:

• Verify your pharmacy: Confirm that the compounding pharmacy filling your prescription is licensed in your state and, if a 503B facility, registered with the FDA
• Understand your prescription: Compounded ketamine is not an FDA-approved product. It is prepared by a pharmacy based on a prescriber's order and does not undergo the same approval process as manufactured drugs like Spravato (esketamine)
• Ask about testing: Inquire whether your pharmacy conducts potency and sterility testing on its ketamine preparations
• Know your state's rules: Regulations vary significantly by state, and what is permitted in one jurisdiction may not be allowed in another
• Report adverse events: If you experience unexpected side effects, report them to your prescriber and consider filing a report with the FDA MedWatch system

The Spravato Factor

The availability of FDA-approved esketamine (Spravato) as a nasal spray for treatment-resistant depression continues to influence the compounding regulatory conversation. Manufacturers and some regulators have argued that the existence of an approved product reduces the justification for compounding ketamine for the same indication. Under FDA rules, compounding is generally permitted only when there is a clinical need that cannot be met by a commercially available product.

However, proponents of compounding argue that:

• Spravato is limited to treatment-resistant depression and is not approved for pain, PTSD, anxiety, or other conditions treated with ketamine
• Spravato must be administered in a certified healthcare facility under a Risk Evaluation and Mitigation Strategy (REMS), making it inaccessible for many patients
• The cost of Spravato treatment is significantly higher than compounded ketamine for many patients
• Racemic ketamine and esketamine are pharmacologically different, and some patients respond to one but not the other

This debate remains unresolved and will likely continue to shape regulatory policy.

Looking Ahead

Several regulatory developments are expected or possible in the remainder of 2026:

• Finalized FDA guidance on compounding quality standards that could establish more uniform national requirements
• Congressional attention: Legislation has been proposed that would create a specific regulatory pathway for compounded controlled substances used in psychiatric treatment
• Industry self-regulation: Trade organizations representing telehealth ketamine companies are developing voluntary standards for clinical protocols, pharmacy partnerships, and patient safety monitoring
• Post-marketing surveillance: Efforts to establish registries or reporting systems that track outcomes and adverse events from compounded ketamine use across providers

Summary

The regulatory environment for compounded ketamine in 2026 reflects the tension between expanding patient access and ensuring safety and quality. Federal agencies are increasing enforcement while states pursue varied approaches. Patients and providers should stay informed about their local regulatory requirements and prioritize working with reputable, compliant pharmacies and prescribers. As the field matures, clearer and more consistent regulatory frameworks are likely to emerge, potentially improving both safety and access.

References

• FDA Compounding — U.S. Food and Drug Administration — FDA overview of compounding regulations and enforcement actions
• DEA Telehealth Prescribing — Drug Enforcement Administration — Current DEA rules for controlled substance prescribing via telehealth
• NABP Compounding Standards — National Association of Boards of Pharmacy — State pharmacy board resources and compounding oversight information
• Ketamine as a Schedule III Substance — DEA Diversion Control Division — Scheduling classification and regulatory implications
• Compounding Quality Act (Section 503A and 503B) — U.S. Congress — The federal law establishing the current compounding regulatory framework